Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Brognard

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Nature Communications|July 2, 2021
Serine-linked PARP1 auto-modification controls PARP inhibitor responseEvgeniia Prokhorova, Florian Zobel, Rebecca Smith, et al.
NPJ Genomic Medicine|June 29, 2018
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary originPedro Torres-Ayuso, Sudhakar Sahoo, Garry Ashton, et al.
Cell Chemical Biology|November 28, 2023
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancerPedro Torres-Ayuso, Meghri Katerji, Dawid Mehlich, et al.
Nature Communications|May 23, 2014
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitorsAnna A Marusiak, Zoe C Edwards, Willy Hugo, et al.
Molecular Cancer Therapeutics|June 10, 2024
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to RadiotherapyTriet Nguyen, Francesca A Carrieri, Nick Connis, et al.
Molecular Cancer Therapeutics|April 26, 2024
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapyTriet Nguyen, Francesca Anna Carrieri, Nick Connis, et al.
Molecular Cancer Therapeutics|June 2, 2026
Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck CancersMeghri Katerji, Maxine R Rubin, Eric Lindberg, et al.
Cancer Research|December 6, 2015
Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon TumorigenesisAnna A Marusiak, Natalie L Stephenson, Hayeon Baik, et al.
Cancer Discovery|January 26, 2021
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through MerlinPedro Torres-Ayuso, Elvira An, Katherine M Nyswaner, et al.
Cancer Cell|December 16, 2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Nature Communications|July 2, 2021
Serine-linked PARP1 auto-modification controls PARP inhibitor responseEvgeniia Prokhorova, Florian Zobel, Rebecca Smith, et al.
NPJ Genomic Medicine|June 29, 2018
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary originPedro Torres-Ayuso, Sudhakar Sahoo, Garry Ashton, et al.
Cell Chemical Biology|November 28, 2023
PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancerPedro Torres-Ayuso, Meghri Katerji, Dawid Mehlich, et al.
Nature Communications|May 23, 2014
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitorsAnna A Marusiak, Zoe C Edwards, Willy Hugo, et al.
Molecular Cancer Therapeutics|June 10, 2024
TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to RadiotherapyTriet Nguyen, Francesca A Carrieri, Nick Connis, et al.
Molecular Cancer Therapeutics|April 26, 2024
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapyTriet Nguyen, Francesca Anna Carrieri, Nick Connis, et al.
Molecular Cancer Therapeutics|June 2, 2026
Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck CancersMeghri Katerji, Maxine R Rubin, Eric Lindberg, et al.
Cancer Research|December 6, 2015
Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon TumorigenesisAnna A Marusiak, Natalie L Stephenson, Hayeon Baik, et al.
Cancer Discovery|January 26, 2021
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through MerlinPedro Torres-Ayuso, Elvira An, Katherine M Nyswaner, et al.
Cancer Cell|December 16, 2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Pageof 6